Select a community
ALS including PLS and PMA
Find out more about the PatientsLikeMe
ALS Community
Home > Community Treatment Reports > Effexor (venlafaxine) Treatment Report
What is Effexor?

EFFEXOR is a brand name of the drug venlaflaxine, a prescription medicine used to treat depression, generalized anxiety disorder (also called "GAD"), and social anxiety disorder in adults.

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Depression 7 1
Anxiety 1 0
Emotional lability 1 0
Other 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
1 100%
Moderate
0 0%
Mild
0 0%
None
0 0%

Most commonly reported side effects

palpatations
1 100%
Shortness of breath
1 100%
felt flat
1 100%
  • Mild
  • Moderate
  • Severe

Dosages

  daily 100 mg daily 150 mg daily 300 mg daily
  1 Number of Patients: 1 1 Number of Patients: 1 3 Number of Patients: 3 2 Number of Patients: 2  

Stop Reasons

Why Patients Stopped Taking Effexor (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice
2 40% Doctor's advice: 40%
Side effects too severe
2 40% Side effects too severe: 40%
Did not seem to work
1 20% Did not seem to work: 20%
Course of treatment ended
1 20% Course of treatment ended: 20%

See all 5 patients who’ve stopped taking Effexor

Currently Taking Effexor

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
0
0
1
2
1

Stopped Taking Effexor

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
3
0
2

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
1 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
1 100%
Somewhat
0 0%
A little
0 0%
Not at all
0 0%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
0 0%
< $25
1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 21, 2009.